Journal
INTERNATIONAL JOURNAL OF EMERGENCY MEDICINE
Volume 11, Issue -, Pages -Publisher
BMC
DOI: 10.1186/s12245-018-0215-6
Keywords
Anticoagulants; Haemorrhage; Non-vitamin K antagonist oral anticoagulants; Dabigatran; Rivaroxaban; Edoxaban; Apixaban; Prothrombin complex concentrates; Anticoagulant reversal
Categories
Funding
- CSL Behring
Ask authors/readers for more resources
BackgroundBleeding complications are a risk associated with all anticoagulants. Currently, the treatment options for the management of direct oral anticoagulant (DOAC)-associated bleeding are limited. Prothrombin complex concentrates (PCCs) have been proposed as a potential therapeutic option, and evidence regarding their use is increasing.ReviewMany studies supporting PCC have used preclinical models and healthy volunteers; however, more recently, observational studies have further improved insight into current DOAC reversal strategies. Multiple clinical practice guidelines now specifically suggest use of PCCs for this indication. Specific reversal agents for Factor Xa inhibitors may become available in the near future, but data on their efficacy are still emerging.ConclusionsUltimately, a multimodal approach may be the optimal strategy to restore haemostasis in patients presenting with DOAC-associated coagulopathy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available